Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/13125
Title: | Antibiotic policy | Authors: | GYSSENS, Inge | Issue Date: | 2011 | Publisher: | ELSEVIER SCIENCE BV | Source: | INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 38, p. 11-20 | Abstract: | There is a clear association between antibiotic use and resistance both on individual and population levels. In the European Union, countries with large antibiotic consumption have higher resistance rates. Antibiotic resistance leads to failed treatments, prolonged hospitalisations, increased costs and deaths. With few new antibiotics in the Research & Development pipeline, prudent antibiotic use is the only option to delay the development of resistance. Antibiotic policy consists of prescribing strategies to optimise the indication, selection, dosing, route of administration, duration and timing of antibiotic therapy to maximise clinical cure or prevention of infection whilst limiting the unintended consequences of antibiotic use, including toxicity and selection of resistant microorganisms. A secondary goal is to reduce healthcare costs without adversely affecting the quality of care. The purpose of this paper is to provide the evidence base of prudent antibiotic policy. Special emphasis is placed on urinary tract infections. The value and support of antibiotic committees, guidelines, ID consultants and/or antimicrobial stewardship teams to prolong the efficacy of available antibiotics will be discussed. (C) 2011 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved. | Notes: | [Gyssens, Inge C.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Inst Infect Inflammat & Immun N4i, NL-6525 ED Nijmegen, Netherlands. [Gyssens, Inge C.] Radboud Univ Nijmegen, Med Ctr, Dept Med, NL-6525 ED Nijmegen, Netherlands. [Gyssens, Inge C.] Canisius Wilhelmina Hosp, Dept Med Microbiol & Infect Dis, Nijmegen, Netherlands. [Gyssens, Inge C.] Hasselt Univ, Diepenbeek, Belgium. | Keywords: | Antibiotic policy;Antimicrobial stewardship;Antimicrobial resistance;Guidelines;Pharmacokinetics;Pharmacodynamics;Urinary tract infections | Document URI: | http://hdl.handle.net/1942/13125 | ISSN: | 0924-8579 | e-ISSN: | 1872-7913 | DOI: | 10.1016/j.ijantimicag.2011.09.002 | ISI #: | 000298141200003 | Rights: | 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2013 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
gyssens1.pdf Restricted Access | Published version | 587.08 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
31
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
42
checked on Apr 30, 2024
Page view(s)
14
checked on Sep 7, 2022
Download(s)
10
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.